Next Generation Sequencing (NGS) Global market - Forecast to 2022

1 EXECUTIVE SUMMARY 22

2 INTRODUCTION 33

• 2.1 KEY TAKE AWAYS 33
• 2.2 REPORT DESCRIPTION 33
• 2.3 MARKETS COVERED 34
• 2.4 STAKEHOLDERS 36
• 2.5 RESEARCH METHODOLOGY 37
  • 2.5.1 MARKET SIZE ESTIMATION 38
  • 2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION 41
  • 2.5.3 SECONDARY SOURCES 42
  • 2.5.4 PRIMARY SOURCES 42
  • 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 43
  • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 43
  • 2.5.7 ASSUMPTIONS 44

3 MARKET ANALYSIS 45

• 3.1 INTRODUCTION 45
• 3.2 MARKET SEGMENTATION 46
• 3.3 FACTORS INFLUENCING MARKET 48
  • 3.3.1 DRIVERS AND OPPORTUNITIES 48
    • 3.3.1.1 Reduced cost and high speed 48
    • 3.3.1.2 Increased usage in clinical diagnosis 49
    • 3.3.1.3 Switch to NGS from microarray technology 51
    • 3.3.1.4 New & emerging applications of ngs technology 52
    • 3.3.1.5 Growth of personalized medicine 53
    • 3.3.1.6 Increased medical spending 53
  • 3.3.2 RESTRAINTS AND THREATS 54
    • 3.3.2.1 Complications in NGS data storage 54
    • 3.3.2.2 Standardization of NGS for diagnostic application 55
    • 3.3.2.3 Grants and funding for NGS infrastructure 56
    • 3.3.2.4 Lack of skilled labor 56
    • 3.3.2.5 Huge and complex NGS data interpretation 57
    • 3.3.2.6 Ethical and legal issues to NGS 58
• 3.4 TECHNOLOGICAL ADVANCEMENTS 59
  • 3.4.1 NANOPORE SEQUENCING BASED TECHNIQUES 59
    • 3.4.1.1 Electronic biosciences nanopore sequencing 59
    • 3.4.1.2 Roche’s nanotag chemistry 59
    • 3.4.1.3 Nabsys nanopore sequencer 59
    • 3.4.1.4 Stratos nanopore sequencing 60
  • 3.4.2 ELECTRONIC OPTICA’S MAD-LEEM 60
  • 3.4.3 GENAPSYS GENIUS 60
  • 3.4.4 LASERGEN’S LIGHTENING TERMINATOR CHEMISTRY 60
  • 3.4.5 QUANTUMDX HANDHELD SEQUENCING INSTRUMENT 61
  • 3.4.6 ZS GENETICS ADF-STEM 61
• 3.5 REGULATORY AFFAIRS 61
  • 3.5.1 U.S. 61
  • 3.5.2 EUROPE 62
  • 3.5.3 CHINA 63
  • 3.5.4 INDIA 64
  • 3.5.5 JAPAN 64
• 3.6 PORTER’S FIVE FORCE ANALYSIS 65
  • 3.6.1 THREAT OF NEW ENTRANTS 66
  • 3.6.2 THREAT OF SUBSTITUTES 66
  • 3.6.3 BARGAINING POWER OF SUPPLIERS 67
  • 3.6.4 BARGAINING POWER OF BUYERS 67
  • 3.6.5 COMPETITIVE RIVALRY 68
• 3.7 PATENT TRENDS 68
• 3.8 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 70

4 NEXT GENERATION SEQUENCING GLOBAL MARKET, BY TECHNOLOGY 72

• 4.1 INTRODUCTION 72
• 4.2 REVERSIBLE TERMINATOR SEQUENCING 77
• 4.3 ION SEMICODUCTOR SEQUENCING 80
• 4.4 SEQUENCING BY LIGATION 82
• 4.5 SINGLE MOLECULE REAL-TIME SEQUENCING (SMRT) 85
• 4.6 OTHERS 87

5 NGS GLOBAL MARKET, BY PRODUCT TYPE 92

• 5.1 INTRODUCTION 92
  • 5.1.1 INSTRUMENTS 94
  • 5.1.2 SERVICES 98
    • 5.1.2.1 Data analysis services 100
    • 5.1.2.2 Sequencing services 102
  • 5.1.3 WORKFLOW PRODUCTS 104

6 NEXT-GENERATION SEQUENCING GLOBAL MARKET, BY APPLICATION 107

• 6.1 INTRODUCTION 107
• 6.2 NGS GLOBAL APPLICATION MARKET, BY PROCESS 107
  • 6.2.1 GENOMICS 109
    • 6.2.1.1 Whole genome sequencing 112
    • 6.2.1.2 Exome sequencing 115
    • 6.2.1.3 Target resequencing 117
    • 6.2.1.4 De novo sequencing 119
  • 6.2.2 EPIGENOMICS 121
    • 6.2.2.1 CHIP sequencing 124
    • 6.2.2.2 Methyl sequencing 126
  • 6.2.3 TRANSCRIPTOMICS 128
    • 6.2.3.1 RNA sequencing 129
  • 6.2.4 OTHERS 131
• 6.3 NGS GLOBAL APPLICATION MARKET, BY FIELD TYPE 133
  • 6.3.1 DIAGNOSTICS 136
    • 6.3.1.1 Cancer diagnostics 139
    • 6.3.1.2 Infectious disease diagnostics 142
    • 6.3.1.3 Genetic screening 144
    • 6.3.1.4 Transplantation diagnostics 147
  • 6.3.2 DRUG DISCOVERY AND DEVELOPMENT 149
  • 6.3.3 BIOMARKER DISCOVERY 152
  • 6.3.4 AGRICULTURE AND ANIMAL RESEARCH 153
  • 6.3.5 OTHER APPLICATIONS 155

7 NEXT-GENERATION SEQUENCING GLOBAL MARKET, BY END USERS 157

• 7.1 INTRODUCTION 157
• 7.2 ACADEMIC RESEARCH 160
• 7.3 HOSPITALS AND CLINICS 161
• 7.4 BIOTECH/PHARMACEUTICALS 163
• 7.5 OTHER END USERS 165

8 NEXT-GENERATION SEQUENCING GLOBAL MARKET, BY REGION 167

• 8.1 INTRODUCTION 167
• 8.2 NORTH AMERICA 169
  • 8.2.1 U.S. 180
  • 8.2.2 OTHERS 182
• 8.3 EUROPE 185
  • 8.3.1 UNITED KINGDOM (U.K.) 196
  • 8.3.2 GERMANY 198
  • 8.3.3 SPAIN 200
  • 8.3.4 OTHERS 202
• 8.4 ASIA-PACIFIC 204
  • 8.4.1 CHINA 215
  • 8.4.2 SOUTH KOREA 217
  • 8.4.3 AUSTRALIA 219
  • 8.4.4 OTHERS 222
• 8.5 REST OF THE WORLD 224
  • 8.5.1 BRAZIL 234
  • 8.5.2 SOUTH AFRICA 236
  • 8.5.3 MIDDLE EAST 238
  • 8.5.4 OTHERS 240

9 COMPANY DEVELOPMENTS 243

• 9.1 INTRODUCTION 243
  • 9.1.1 NEW PRODUCT LAUNCH AS A MAJOR GROWTH STRATEGY OF NGS MARKET PLAYERS 243
• 9.2 NEW PRODUCT LAUNCH 245
• 9.3 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS 260
• 9.4 ACQUISITIONS 272
• 9.5 OTHER DEVELOPMENTS 275

10 MAJOR PLAYER PROFILES 279

• 10.1 AGILENT TECHNOLOGIES, INC. 279
  • 10.1.1 OVERVIEW 279
  • 10.1.2 FINANCIALS 280
  • 10.1.3 PRODUCT PORTFOLIO 282
  • 10.1.4 KEY DEVELOPMENTS 285
  • 10.1.5 BUSINESS STRATEGY 288
  • 10.1.6 SWOT ANALYSIS 289
• 10.2 BGI (BEIJING GENOMICS INSTITUTE) 290
  • 10.2.1 OVERVIEW 290
  • 10.2.2 FINANCIALS 290
  • 10.2.3 PRODUCT PORTFOLIO 291
  • 10.2.4 KEY DEVELOPMENTS 292
  • 10.2.5 BUSINESS STRATEGY 294
  • 10.2.6 SWOT ANALYSIS 295
• 10.3 DNASTAR, INC. 296
  • 10.3.1 OVERVIEW 296
  • 10.3.2 FINANCIALS 296
  • 10.3.3 PRODUCT PORTFOLIO 296
  • 10.3.4 KEY DEVELOPMENTS 297
  • 10.3.5 BUSINESS STRATEGY 298
  • 10.3.6 SWOT ANALYSIS 299
• 10.4 EUROFIN GENOMICS 300
  • 10.4.1 OVERVIEW 300
  • 10.4.2 FINANCIALS 301
  • 10.4.3 PRODUCT PORTFOLIO 301
  • 10.4.4 KEY DEVELOPMENTS 302
  • 10.4.5 BUSINESS STRATEGY 303
  • 10.4.6 SWOT ANALYSIS 304
• 10.5 ILLUMINA, INC. 305
  • 10.5.1 OVERVIEW 305
  • 10.5.2 FINANCIALS 306
  • 10.5.3 PRODUCT PORTFOLIO 308
  • 10.5.4 KEY DEVELOPMENTS 312
  • 10.5.5 BUSINESS STRATEGY 318
  • 10.5.6 SWOT ANALYSIS 319
• 10.6 OXFORD NANOPORE TECHNOLOGIES LTD 320
  • 10.6.1 OVERVIEW 320
  • 10.6.2 FINANCIALS 320
  • 10.6.3 PRODUCT PORTFOLIO 321
  • 10.6.4 KEY DEVELOPMENTS 321
  • 10.6.5 BUSINESS STRATEGY 322
  • 10.6.6 SWOT ANALYSIS 323
• 10.7 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 324
  • 10.7.1 OVERVIEW 324
  • 10.7.2 FINANCIALS 325
  • 10.7.3 PRODUCT PORTFOLIO 327
  • 10.7.4 KEY DEVELOPMENTS 331
  • 10.7.5 BUSINESS STRATEGY 335
  • 10.7.6 SWOT ANALYSIS 336
• 10.8 QIAGEN N.V. 337
  • 10.8.1 OVERVIEW 337
  • 10.8.2 FINANCIALS 338
  • 10.8.3 PRODUCT PORTFOLIO 340
  • 10.8.4 KEY DEVELOPMENTS 343
  • 10.8.5 BUSINESS STRATEGY 348
  • 10.8.6 SWOT ANALYSIS 349
• 10.9 ROCHE HOLDINGS AG 350
  • 10.9.1 OVERVIEW 350
  • 10.9.2 FINANCIALS 351
  • 10.9.3 PRODUCT PORTFOLIO 354
  • 10.9.4 KEY DEVELOPMENTS 356
  • 10.9.5 BUSINESS STRATEGY 359
  • 10.9.6 SWOT ANALYSIS 360
• 10.10 THERMO FISHER SCIENTIFIC, INC. 361
  • 10.10.1 OVERVIEW 361
  • 10.10.2 FINANCIALS 362
  • 10.10.3 PRODUCT PORTFOLIO 364
  • 10.10.4 KEY DEVELOPMENTS 368
  • 10.10.5 BUSINESS STRATEGY 373